Adelaide Research & Scholarship: Search

Search

Results 21-30 of 79 (Search time: 0.003 seconds).

previous
1
2
3
4
5
6
...
8
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2013	Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab	Price, T.; Hardingham, J.; Lee, C.; Townsend, A.; Wrin, J.; Wilson, K.; Weickhardt, A.; Simes, R.; Murone, C.; Tebbutt, N.
	2014	Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines	Ransom, D.; Wilson, K.; Fournier, M.; Simes, R.; Gebski, V.; Yip, D.; Tebbutt, N.; Karapetis, C.; Ferry, D.; Gordon, S.; Price, T.
	2013	Panitumumab in metastatic colorectal cancer	Hocking, C.; Townsend, A.; Price, T.
	2013	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.	Siu, L.; Shapiro, J.; Jonker, D.; Karapetis, C.; Zalcberg, J.; Simes, J.; Couture, F.; Moore, M.; Price, T.; Siddiqui, J.; Nott, L.; Charpentier, D.; Liauw, W.; Sawyer, M.; Jefford, M.; Magoski, N.; Haydon, A.; Walters, I.; Ringash, J.; Tu, D.; et al.
	2013	The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors	Rosen, L.; Lipton, L.; Price, T.; Belman, N.; Boccia, R.; Hurwitz, H.; Stephenson Jr, J.; Wirth, L.; McCoy, S.; Hei, Y.; Hsu, C.; Tebbutt, N.
	2016	Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer	Price, T.; Kim, T.W.; Li, J.; Cascinu, S.; Ruff, P.; Suresh, A.S.; Thomas, A.; Tjulandin, S.; Guan, X.; Peeters, M.
	2016	Selective internal radiation therapy for liver metastases from colorectal cancer	Townsend, A.; Chong, L.; Karapetis, C.; Price, T.
	2015	Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer	Price, T.; Bruhn, M.; Lee, C.; Hardingham, J.; Townsend, A.; Mann, K.; Simes, J.; Weickhardt, A.; Wrin, J.; Wilson, K.; Gebski, V.; Van Hazel, G.; Robinson, B.; Cunningham, D.; Tebbutt, N.
	2013	Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy	Padman, S.; Padbury, R.; Beeke, C.; Karapetis, C.; Bishnoi, S.; Townsend, A.; Maddern, G.; Price, T.
	2015	Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer	Weickhardt, A.; Williams, D.; Lee, C.; Chionh, F.; Simes, J.; Murone, C.; Wilson, K.; Parry, M.; Asadi, K.; Scott, A.; Punt, C.; Nagtegaal, I.; Price, T.; Mariadason, J.; Tebbutt, N.